<DOC>
	<DOC>NCT02131298</DOC>
	<brief_summary>This study is designed to evaluate the potential effect of itraconazole on the pharmacokinetics of palbociclib.</brief_summary>
	<brief_title>Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<criteria>Healthy male and/or female subjects of nonchildbearing potential between the ages of 18 and 55 years, inclusive. Body mass index of 17.5 to 30.5 kg/m2, and a total body weight &gt;50 kg (110 lbs). Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic diseases. Any condition possibly affecting drug absorption. A positive urine drug screen or alcohol breath test. Pregnant female subjects; breast feeding female subjects, female subjects of childbearing potential, male subjects with partners currently pregnant, male subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for 90 days after the last dose of investigational product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Palbociclib</keyword>
	<keyword>Itraconazole</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug-Drug Interaction Study</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>